These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32395869)

  • 1. CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
    Chen Y; Tang J; Lu T; Liu F
    Thorac Cancer; 2020 Jul; 11(7):1848-1860. PubMed ID: 32395869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.
    Wang F; Zhang L; Sai B; Wang L; Zhang X; Zheng L; Tang J; Li G; Xiang J
    Cancer Biol Ther; 2020; 21(1):61-71. PubMed ID: 31559898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
    Jin T; Li D; Yang T; Liu F; Kong J; Zhou Y
    Oncol Rep; 2019 Aug; 42(2):717-725. PubMed ID: 31173266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GALNT2 promotes cell proliferation, migration, and invasion by activating the Notch/Hes1-PTEN-PI3K/Akt signaling pathway in lung adenocarcinoma.
    Wang W; Sun R; Zeng L; Chen Y; Zhang N; Cao S; Deng S; Meng X; Yang S
    Life Sci; 2021 Jul; 276():119439. PubMed ID: 33785338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
    Zhu HE; Yin JY; Chen DX; He S; Chen H
    Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actin-like protein 8 promotes cell proliferation, colony-formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells.
    Ma S; Wang X; Zhang Z; Liu D
    Thorac Cancer; 2020 Mar; 11(3):526-536. PubMed ID: 31962007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma.
    Wang Y; Mei X; Song W; Wang C; Qiu X
    BMC Pulm Med; 2022 Jul; 22(1):272. PubMed ID: 35842617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
    Wang J; Zhou P; Wang X; Yu Y; Zhu G; Zheng L; Xu Z; Li F; You Q; Yang Q; Zhuo W; Sun J; Chen Z
    Cell Prolif; 2019 May; 52(3):e12592. PubMed ID: 30848009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m
    Du X; Cheng C; Yang Y; Fan B; Wang P; Xia H; Ni X; Liu Q; Lu L; Wei L
    Mol Carcinog; 2024 May; 63(5):962-976. PubMed ID: 38411298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
    Hsieh MS; Lin MW; Lee YH
    Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
    Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
    Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
    Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
    PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
    Hussmann D; Madsen AT; Jakobsen KR; Luo Y; Sorensen BS; Nielsen AL
    Oncotarget; 2017 May; 8(20):33300-33315. PubMed ID: 28418902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
    Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
    Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-9-5p Promotes Lung Adenocarcinoma Cell Proliferation, Migration and Invasion by Targeting ID4.
    Zhu K; Lin J; Chen S; Xu Q
    Technol Cancer Res Treat; 2021; 20():15330338211048592. PubMed ID: 34723712
    [No Abstract]   [Full Text] [Related]  

  • 20. CircPRKCI regulates proliferation, migration and cycle of lung adenocarcinoma cells by targeting miR-219a-5p-regulated CAMK1D.
    Sui MH; Zhang WW; Geng DM; Sun DJ
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1899-1909. PubMed ID: 33660800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.